Scientist and entrepreneur, Dr. K Anji Reddy establishes Dr. Reddy's Laboratories with a vision of making medicines accessible to the millions in India. The company begins by making the active ingredient Methyldopa – a hypertension drug that was unavailable in India until 1985. We supply Methyldopa to Merck, Sharp, Dohme Corp, manufacturers of Aldomet, and export it to West Germany, Yugoslavia, Bangladesh, Kenya and Canada. On the back of its success with active ingredients, Dr Reddy’s begins developing formulations. By 1990, Dr. Reddy’s is the first Indian pharma company to export Norfloxacin and Ciprofloxacin to Europe and Far East.

Realizing the importance of making innovative medicines more accessible not just in India, but the world, Dr. Reddy’s focuses on creating world-class capabilities. It begins constructing a finished dosage facility in Hyderabad. It expands globally and enters highly regulated markets like the USA. By 2000 Dr. Reddy's becomes India's third largest pharmaceutical company. This gives Dr. Reddy’s the critical mass to compete, raise resources as well as attract and retain talent.

In 2001 Dr. Reddy’s becomes the first Asia Pacific pharmaceutical company, outside Japan, to list on the New York Stock Exchange. This listing gives the company visibility in the world’s largest pharmaceutical market and ensures stronger financial support. Dr. Reddy’s comes up trumps against all odds by not only having its stock oversubscribed but also becoming the best performing IPO for the year. Dr. Reddy’s also becomes the first Indian pharmaceutical company to obtain 180-day exclusive marketing rights for generic Fluoxetine 40 mg capsules. By doing so, Dr. Reddy’s manages to make affordable medicines available to millions affected by clinical depression.

Staying sharply focused on patient needs, Dr. Reddy’s focuses on making expensive therapies against disease, affordable. In 2007, Dr. Reddy’s launches the world’s first biosimilar monoclonal antibody (mAb), Rituximab. The product makes treatment of cancers like non-Hodgkin’s lymphoma, accessible to millions of patients worldwide. In 2010, Dr. Reddy’s launches the first biosimilar darbepoetin alfa in the world, and brings relief to millions of anaemia patients.

Taking a holistic view of patient needs, Dr Reddy’s focuses on creating and rolling out a number of programs to help patients, doctors and caregivers better managing disease. Programs like Sparsh and PromiusPromise™ go a long way in helping patients get treatment and manage disease better.

Dr. Reddy’s acquires OctoPlus N.V., Netherlands, a service-based specialty pharmaceutical company. With this, Dr. Reddy’s significantly strengthens its capabilities in proprietary drug delivery technologies and difficult-to-formulate APIs.

Dr. Reddy’s acquires OctoPlus N.V., Netherlands, a service-based specialty pharmaceutical company. With this, Dr. Reddy’s significantly strengthens its capabilities in proprietary drug delivery technologies and difficult-to-formulate APIs.